相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。SAFETY AND EFFICACY OF MK-8669 (RIDAFOROLIMUS) + MK-2206 (AKT INHIBITOR) IN PATIENTS WITH ADVANCED BREAST CANCER WITH PI3K PATHWAY DEPENDENCE
S. Gupta et al.
ANNALS OF ONCOLOGY (2014)
Roles of PTEN (Phosphatase and Tensin Homolog) in Gastric Cancer Development and Progression
Wen-Ting Xu et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
MicroRNA-375 inhibits colorectal cancer growth by targeting PIK3CA
Yihui Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
miR-17 inhibitor suppressed osteosarcoma tumor growth and metastasis via increasing PTEN expression
Yong Gao et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2014)
Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
Jennifer R. Brown et al.
BLOOD (2014)
Phase 1 and Pharmacodynamic Trial of Everolimus in Combination With Cetuximab in Patients With Advanced Cancer
Christine A. Ciunci et al.
CANCER (2014)
Molecular Determinants of Outcome With Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
Helen J. Mackay et al.
CANCER (2014)
A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
Ana M. Molina et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors
Geoffrey I. Shapiro et al.
CLINICAL CANCER RESEARCH (2014)
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
Kyriakos P. Papadopoulos et al.
CLINICAL CANCER RESEARCH (2014)
Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy
Cristina Saura et al.
CLINICAL CANCER RESEARCH (2014)
A Phase I Study of Temsirolimus and Thoracic Radiation in Non-Small-Cell Lung Cancer
Saiama N. Waqar et al.
CLINICAL LUNG CANCER (2014)
The Search Continues Looking for Predictive Biomarkers for Response to Mammalian Target of Rapamycin Inhibition in Endometrial Cancer
Larissa A. Meyer et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Phase I study of PF-04691502, a small-molecule, oral, dual inhibitor of PI3K and mTOR, in patients with advanced cancer
Carolyn D. Britten et al.
INVESTIGATIONAL NEW DRUGS (2014)
Efficacy of Everolimus in Patients with Advanced Renal Cell Carcinoma Refractory or Intolerant to VEGFR-TKIs and Safety Compared with Prior VEGFR-TKI Treatment
Renpei Kato et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2014)
Temsirolimus enhances the efficacy of cetuximab in colon cancer through a CIP2A-dependent mechanism
Hsei-Wei Wang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Phase I Dose-Escalation Study of 5-Day Intermittent Oral Lapatinib Therapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer
A. Jo Chien et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma
Thomas E. Hutson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Second Malignant Neoplasms in Patients With Cowden Syndrome With Underlying Germline PTEN Mutations
Joanne Ngeow et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2-Dependent and Other Solid Tumors
Leena Gandhi et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors
L. Rhoda Molife et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2014)
Phase I Safety and Pharmacokinetic Study of the PI3K/mTOR Inhibitor SAR245409 ( XL765) in Combination with Erlotinib in Patients with Advanced Solid Tumors
Pasi A. Jaenne et al.
JOURNAL OF THORACIC ONCOLOGY (2014)
Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles
Melissa K. McConechy et al.
MODERN PATHOLOGY (2014)
PTEN Is a Potent Suppressor of Small Cell Lung Cancer
Min Cui et al.
MOLECULAR CANCER RESEARCH (2014)
Perifosine treatment in chronic lymphocytic leukemia: results of a phase II clinical trial and in vitro studies
Daphne R. Friedman et al.
LEUKEMIA & LYMPHOMA (2014)
PI3K and cancer: lessons, challenges and opportunities
David A. Fruman et al.
NATURE REVIEWS DRUG DISCOVERY (2014)
PTEN is a protein tyrosine phosphatase for IRS1
Yuji Shi et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2014)
Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2014)
A Phase I Study of Temsirolimus and Bryostatin-1 in Patients With Metastatic Renal Cell Carcinoma and Soft Tissue Sarcoma
Elizabeth R. Plimack et al.
ONCOLOGIST (2014)
Molecular Subtypes of Glioblastoma Are Relevant to Lower Grade Glioma
Xiaowei Guan et al.
PLOS ONE (2014)
Combined PTEN Mutation and Protein Expression Associate with Overall and Disease-Free Survival of Glioblastoma Patients
Jie Xu et al.
TRANSLATIONAL ONCOLOGY (2014)
PTEN function: the long and the short of it
Benjamin D. Hopkins et al.
TRENDS IN BIOCHEMICAL SCIENCES (2014)
被撤回的出版物: MicroRNA-128 promotes proliferation in osteosarcoma cells by downregulating PTEN (Retracted article. See April, 2017)
Lei Shen et al.
TUMOR BIOLOGY (2014)
Temsirolimus combined with sorafenib in hepatocellular carcinoma: a phase I dose-finding trial with pharmacokinetic and biomarker correlates
R. K. Kelley et al.
ANNALS OF ONCOLOGY (2013)
A phase I trial of the IGF-1R antibody Cixutumumab in combination with temsirolimus in patients with metastatic breast cancer
Cynthia X. Ma et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours
D. W. Bowles et al.
BRITISH JOURNAL OF CANCER (2013)
A phase-1b study of everolimus plus paclitaxel in patients with small-cell lung cancer
J. M. Sun et al.
BRITISH JOURNAL OF CANCER (2013)
Targeting EGFR and PI3K pathways in ovarian cancer
S. Glaysher et al.
BRITISH JOURNAL OF CANCER (2013)
Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial
N. Colombo et al.
BRITISH JOURNAL OF CANCER (2013)
A phase II study evaluating the toxicity and efficacy of single-agent temsirolimus in chemotherapy-naive castration-resistant prostate cancer
K. Kruczek et al.
BRITISH JOURNAL OF CANCER (2013)
Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO
I. Ray-Coquard et al.
BRITISH JOURNAL OF CANCER (2013)
Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells
Maira M. Pires et al.
CANCER BIOLOGY & THERAPY (2013)
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528
Shirish M. Gadgeel et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Phase II Study of Everolimus in Patients with Metastatic Colorectal Adenocarcinoma Previously Treated with Bevacizumab-, Fluoropyrimidine-, Oxaliplatin-, and Irinotecan-Based Regimens
Kimmie Ng et al.
CLINICAL CANCER RESEARCH (2013)
Phase Ib study of tivozanib (AV-951) in combination with temsirolimus in patients with renal cell carcinoma
M. N. Fishman et al.
EUROPEAN JOURNAL OF CANCER (2013)
Phase 2 Trial of Single-agent Everolimus in Chemotherapy-naive Patients with Castration-resistant Prostate Cancer (SAKK 08/08)
Arnoud J. Templeton et al.
EUROPEAN UROLOGY (2013)
Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer
Jesus C. Fabregas et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2013)
A mosaic PTEN mutation causing Cowden syndrome identified by deep sequencing
Colin C. Pritchard et al.
GENETICS IN MEDICINE (2013)
Phase II study of temsirolimus (CCI-779) in women with recurrent, unresectable, locally advanced or metastatic carcinoma of the cervix. A trial of the NCIC Clinical Trials Group (NCIC CTG IND 199)
A. V. Tinker et al.
GYNECOLOGIC ONCOLOGY (2013)
Phase II trial of combination bevacizumab and temsirolimus in the treatment of A recurrent or persistent endometrial carcinoma: A Gynecologic Oncology Group study
Edwin A. Alvarez et al.
GYNECOLOGIC ONCOLOGY (2013)
A dose-finding study of temsirolimus and liposomal doxorubicin for patients with recurrent and refractory bone and soft tissue sarcoma
K. A. Thornton et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
RTOG 0913: A Phase 1 Study of Daily Everolimus (RAD001) in Combination With Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma
Prakash Chinnaiyan et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2013)
Phase I clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer
Prasanth Ganesan et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome
Ivana Gojo et al.
INVESTIGATIONAL NEW DRUGS (2013)
Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer
Marina N. Nikiforova et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2013)
Randomized Phase III Placebo-Controlled Trial of Letrozole Plus Oral Temsirolimus As First-Line Endocrine Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Toward a NOTCH1/FBXW7/RAS/PTEN-Based Oncogenetic Risk Classification of Adult T-Cell Acute Lymphoblastic Leukemia: A Group for Research in Adult Acute Lymphoblastic Leukemia Study
Amelie Trinquand et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Results of an International Randomized Phase III Trial of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus Versus Placebo to Control Metastatic Sarcomas in Patients After Benefit From Prior Chemotherapy
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Everolimus for Previously Treated Advanced Gastric Cancer: Results of the Randomized, Double-Blind, Phase III GRANITE-1 Study
Atsushi Ohtsu et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A phase I study of ridaforolimus in adult Chinese patients with advanced solid tumors
Lian Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells
Weiyun Wu et al.
MOLECULAR CANCER (2013)
Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial
Gary K. Schwartz et al.
LANCET ONCOLOGY (2013)
Phase I clinical, pharmacokinetic, and pharmacodynamic study of the Akt-inhibitor triciribine phosphate monohydrate in patients with advanced hematologic malignancies
Deepa Sampath et al.
LEUKEMIA RESEARCH (2013)
Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer
Brian M. Wolpin et al.
ONCOLOGIST (2013)
A phase II study of temsirolimus and erlotinib in patients with recurrent and/or metastatic, platinum-refractory head and neck squamous cell carcinoma
Julie E. Bauman et al.
ORAL ONCOLOGY (2013)
Overall Survival Benefits for Combining Targeted Therapy as Second-Line Treatment for Advanced Non-Small-Cell-Lung Cancer: A Meta-Analysis of Published Data
Wei-Xiang Qi et al.
PLOS ONE (2013)
Analysis of PTEN Methylation Patterns in Soft Tissue Sarcomas by MassARRAY Spectrometry
Liang Yin et al.
PLOS ONE (2013)
Four MicroRNAs Promote Prostate Cell Proliferation with Regulation of PTEN and Its Downstream Signals In Vitro
Ling Tian et al.
PLOS ONE (2013)
High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study
Yue-E Liu et al.
RADIATION ONCOLOGY (2013)
Phase I trial of the combination of the Akt inhibitor nelfinavir and chemoradiation for locally advanced rectal cancer
Jeroen Buijsen et al.
RADIOTHERAPY AND ONCOLOGY (2013)
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
Dominique Werner et al.
CANCER MEDICINE (2013)
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Mark Wade et al.
NATURE REVIEWS CANCER (2013)
Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer
Antje Krohn et al.
AMERICAN JOURNAL OF PATHOLOGY (2012)
Phase I safety, pharmacokinetic, and pharmacodynamic study of the oral phosphatidylinositol-3-kinase and mTOR inhibitor BGT226 in patients with advanced solid tumors
B. Markman et al.
ANNALS OF ONCOLOGY (2012)
MiR-124 suppresses cell proliferation in hepatocellular carcinoma by targeting PIK3CA
Qingbo Lang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2012)
A reinvestigation of somatic hypermethylation at the PTEN CpG island in cancer cell lines
Luke B. Hesson et al.
BIOLOGICAL PROCEDURES ONLINE (2012)
Alternative dosing of dual PI3K and MEK inhibition in cancer therapy
Elina Jokinen et al.
BMC CANCER (2012)
Phase II trial of temsirolimus in patients with metastatic breast cancer
Gini F. Fleming et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8055 in advanced solid tumours and lymphoma
A. Naing et al.
BRITISH JOURNAL OF CANCER (2012)
Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a Phase I Multiple Myeloma Research Consortium study
Andrzej J. Jakubowiak et al.
BRITISH JOURNAL OF HAEMATOLOGY (2012)
Two Phase 2 Trials of the Novel Akt Inhibitor Perifosine in Patients With Advanced Renal Cell Carcinoma After Progression on Vascular Endothelial Growth Factor-Targeted Therapy
Daniel C. Cho et al.
CANCER (2012)
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
David S. Hong et al.
CLINICAL CANCER RESEARCH (2012)
The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
Toshio Shimizu et al.
CLINICAL CANCER RESEARCH (2012)
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies
D. Mahadevan et al.
EUROPEAN JOURNAL OF CANCER (2012)
Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma
Birgit Geoerger et al.
EUROPEAN JOURNAL OF CANCER (2012)
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
Antonella De Luca et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2012)
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Jeremy S. Logue et al.
GENES & DEVELOPMENT (2012)
Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer
Siqing Fu et al.
GYNECOLOGIC ONCOLOGY (2012)
Cutaneous T cell lymphoma: update on treatment
Uwe Wollina
INTERNATIONAL JOURNAL OF DERMATOLOGY (2012)
Phase I study of temsirolimus in combination with EKB-569 in patients with advanced solid tumors
Alan H. Bryce et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies
Maarten J. Deenen et al.
INVESTIGATIONAL NEW DRUGS (2012)
Phase II Study of the Mammalian Target of Rapamycin Inhibitor Ridaforolimus in Patients With Advanced Bone and Soft Tissue Sarcomas
Sant P. Chawla et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Combinatorial drug therapy for cancer in the post-genomic era
Bissan Al-Lazikani et al.
NATURE BIOTECHNOLOGY (2012)
Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer
Guy Jerusalem et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Role of PTEN promoter methylation in tamoxifen-resistant breast cancer cells
Nguyen Thi Thuy Phuong et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Combination mTOR and IGF-1R Inhibition: Phase I Trial of Everolimus and Figitumumab in Patients with Advanced Sarcomas and Other Solid Tumors
Richard Quek et al.
CLINICAL CANCER RESEARCH (2011)
Phase I Trial of Cixutumumab Combined with Temsirolimus in Patients with Advanced Cancer
Aung Naing et al.
CLINICAL CANCER RESEARCH (2011)
Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line
Haitao Bai et al.
FEBS LETTERS (2011)
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-Shifting the paradigm
Robert J. Kurman et al.
HUMAN PATHOLOGY (2011)
Phase I pharmacokinetic and pharmacodynamic study of triciribine phosphate monohydrate, a small-molecule inhibitor of AKT phosphorylation, in adult subjects with solid tumors containing activated AKT
Christopher R. Garrett et al.
INVESTIGATIONAL NEW DRUGS (2011)
Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial
Paul G. Richardson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Randomized Placebo-Controlled Phase II Trial of Perifosine Plus Capecitabine As Second- or Third-Line Therapy in Patients With Metastatic Colorectal Cancer
Johanna C. Bendell et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
New insights in sarcoma oncogenesis: a comprehensive analysis of a large series of 160 soft tissue sarcomas with complex genomics
Laure Gibault et al.
JOURNAL OF PATHOLOGY (2011)
Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer
Cathy B. Moelans et al.
JOURNAL OF PATHOLOGY (2011)
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer
Ana M. Gonzalez-Angulo et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial
Sylvie Negrier et al.
LANCET ONCOLOGY (2011)
The genomic complexity of primary human prostate cancer
Michael F. Berger et al.
NATURE (2011)
Frequency of Germline PTEN Mutations in Differentiated Thyroid Cancer
Rebecca Nagy et al.
THYROID (2011)
Multimodal Biomarker Investigation on Efficacy and Mechanism of Action for the Mammalian Target of Rapamycin Inhibitor, Temsirolimus, in a Preclinical Mammary Carcinoma OncoMouse Model: A Translational Medicine Study in Support for Early Clinical Development
Xinkang Wang et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Phase 3 Trial of Everolimus for Metastatic Renal Cell Carcinoma Final Results and Analysis of Prognostic Factors
Robert J. Motzer et al.
CANCER (2010)
Putative chemopreventive molecules can increase Nrf2-regulated cell defense in some human cancer cell lines, resulting in resistance to common cytotoxic therapies
Liangao Hu et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with In vitro and In vivo Antitumor Activity
Christine M. Chresta et al.
CANCER RESEARCH (2010)
A Pharmacodynamic Study of Rapamycin in Men with Intermediate- to High-Risk Localized Prostate Cancer
Andrew J. Armstrong et al.
CLINICAL CANCER RESEARCH (2010)
Targeting the PI3K signaling pathway in cancer
Kwok-Kin Wong et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2010)
Akt inhibitors in clinical development for the treatment of cancer
Sumanta Kumar Pal et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
PTEN mutation spectrum in breast cancers and breast hyperplasia
JuLun Yang et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2010)
The PI3K Pathway As Drug Target in Human Cancer
Kevin D. Courtney et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Katharine A. Price et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Inhibitors of phosphatidylinositol-3-kinase in cancer therapy
Nathan T. Ihle et al.
MOLECULAR ASPECTS OF MEDICINE (2010)
Discovery of molecular subtypes in leiomyosarcoma through integrative molecular profiling
A. H. Beck et al.
ONCOGENE (2010)
FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma
Virginia E. Kwitkowski et al.
ONCOLOGIST (2010)
High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia
Alejandro Gutierrez et al.
BLOOD (2009)
Phase II Randomized Study of Neoadjuvant Everolimus Plus Letrozole Compared With Placebo Plus Letrozole in Patients With Estrogen Receptor-Positive Breast Cancer
Jose Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias
M. S. Kim et al.
BRITISH JOURNAL OF CANCER (2008)
Integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer
Katherine Stemke-Hale et al.
CANCER RESEARCH (2008)
PIK3CA mutations and copy number gains in human lung cancers
Hiromasa Yamamoto et al.
CANCER RESEARCH (2008)
Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung
Donatella Malanga et al.
CELL CYCLE (2008)
Phosphatidylinositol 3-Kinase/Akt and Ras/RafMitogen-Activated protein kinase pathway mutations in anaplastic thyroid cancer
Libero Santarpia et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
AKT1E17K in human solid tumours
F. E. Bleeker et al.
ONCOGENE (2008)
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: A phase II California/Pittsburgh cancer consortium trial
Karen G. Chee et al.
CLINICAL GENITOURINARY CANCER (2007)
PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma
J. Abubaker et al.
LEUKEMIA (2007)
PIK3CA mutation and amplification in human lung cancer
Koji Okudela et al.
PATHOLOGY INTERNATIONAL (2007)
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
Gary Hudes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Epigenetic and genetic alterations of PTEN in hepatocellular carcinoma
Li Wang et al.
HEPATOLOGY RESEARCH (2007)
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/Akt pathway in thyroid tumors
Yangang Wang et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2007)
PIK3CA alterations in primary (de novo) and secondary glioblastomas
Daisuke Kita et al.
ACTA NEUROPATHOLOGICA (2007)
PIK3CA gene mutations in pediatric and adult glioblastoma multiforme
Gary L. Gallia et al.
MOLECULAR CANCER RESEARCH (2006)
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced sotid tumours
Stefan R. Vink et al.
RADIOTHERAPY AND ONCOLOGY (2006)
Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis
M Cully et al.
NATURE REVIEWS CANCER (2006)
High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma
K Oda et al.
CANCER RESEARCH (2005)
Exploiting the PI3K/AKT pathway for cancer drug discovery
BT Hennessy et al.
NATURE REVIEWS DRUG DISCOVERY (2005)
PTEN expression in non-small-cell lung cancer:: evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration
CJ Marsit et al.
HUMAN PATHOLOGY (2005)
Frequent mutation of the PIK3CA gene in ovarian and breast cancers
DA Levine et al.
CLINICAL CANCER RESEARCH (2005)
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
LH Saal et al.
CANCER RESEARCH (2005)
PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas
JW Lee et al.
ONCOGENE (2005)
Loss of heterozygosity on 10q23.3 and mutation of tumor suppressor gene PTEN in gastric cancer and precancerous lesions
Yi-Ling Li et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2005)
High frequency of mutations of the PIK3CA gene in human cancers
Y Samuels et al.
SCIENCE (2004)
The biology and clinical relevance of the PTEN tumor suppressor pathway
I Sansal et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
PTEN promoter is methylated in a proportion of invasive breast cancers
S Khan et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
The phosphatidylinositol 3-kinase-AKT pathway in human cancer
I Vivanco et al.
NATURE REVIEWS CANCER (2002)
Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression
B Kwabi-Addo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
分享论文
